GoldenGolden
Advanced Search
Amyris (company)

Amyris (company)

A biotechnology company making specialty ingredients and consumer products out of plant sugars.

Amyris is a biotechnology company making specialty ingredients and consumer products out of plant sugars that is headquartered in Emeryville, California and was founded in 2003 by

Jack Newman, Kinkead Reiling, Neil Renninger, and Vince Martin.

Funding
Series A

On October 12, 2006 Amyris announced completing their series A funding round with $20 million in funding from Khosla Ventures (lead investor), Kleiner Perkins Caufield & Byers (KPCB), and Texas Pacific Group Ventures (TPGV). At the time of receiving their series A funding the company appointed John Melo as the companies CEO. Jay D. Keasling, one of the founders of Amyris, made the following public statement regarding what the company plans on doing with their series A funding:

The completion of this financing validates the strength of Amyris' core technology and signals an important step in the company's growth. These new resources will enable the company to expand its capabilities to address major global health and energy challenges, thereby helping to fulfill the promise of synthetic biology.
Series D

On June 26, 2010 Amyris announced completing their series D funding round with $133 million in funding from Temasek Holdings (lead investor), Total, Procter & Gamble Company, and Cosan S.A..

Private placement

On April 29, 2019 Amyris announced raising $34 million through the sale the private placement of common stock to existing investors. The president and CEO of Amris, John Melo, made the following statement regarding the companies private placement of common stock:

Our long-term investors continue to be encouraged by the performance of our products and technology. We believe they see our capabilities as being essential in disrupting large global markets by delivering the best products to meet consumer needs for natural and sustainable skin care, sweeteners and soon with highest quality and purity CBD. These funds support our plan to retire our May debt maturity and to continue growing our business.
Acquisitions
Draths Corporation

In October 2011 Amyris acquired Draths Corporation for $7 million in stock. The company purchased Draths Corporation for their patents related to the production of synthetic materials using biotechnology and chemistry.

Timeline

July 12, 2010
Amyris raises a $47,800,000 series D round from Temasek.
October 1, 2009
Amyris raises a $41,750,000 series C round from Khosla Ventures and Kleiner Perkins Caufield & Byers.
August 14, 2008
Amyris raises a $21,000,000 series B round from DAG Ventures, Khosla Ventures and Kleiner Perkins Caufield & Byers.
October 12, 2006
Amyris raises a $20,000,000 series A round from Khosla Ventures and Kleiner Perkins Caufield & Byers.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
FinSMEs
June 15, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Amyris, Inc.
May 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer...
Amyris, Inc.
April 9, 2021
www.prnewswire.com:443
/PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its...
Amyris, Inc.
April 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its...
Amyris, Inc.
January 22, 2021
www.prnewswire.com:443
/PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer...
Amyris, Inc.
January 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer...
Amyris, Inc.
December 28, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer...
Amyris, Inc.
December 3, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer...
BioSpace
May 14, 2020
BioSpace
Amyris, Inc. (Nasdaq:AMRS), a leading synthetic biotechnology company with leadership in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, announces that its first health and nutrition ingredient received a validation by a unanimous Panel of Medical Experts as Gene

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.